A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
研究概览
地位
条件
干预/治疗
详细说明
The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Study Physician
- 电话号码:+46 86972000
- 邮箱:medical.info@sobi.com
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 2R7
- University of Alberta - Faculty of Medicine & Dentistry
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
London、Ontario、加拿大、N6A 5A5
- London Health Sciences Centre (LHSC) - University Hospital
-
Toronto、Ontario、加拿大、M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal、Quebec、加拿大、H4A 3J1
- McGill University Health Centre Research Institute
-
-
-
-
Pernambuco
-
Recife、Pernambuco、巴西、52010-010
- Real Hospital Português
-
-
São Paulo
-
Botucatu、São Paulo、巴西、18618-970
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
-
São Paulo、São Paulo、巴西、05403-000
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
-
-
-
-
Lower Saxony
-
Hanover、Lower Saxony、德国、30625
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、德国、50937
- Universitaetsklinikum Koeln
-
Essen、North Rhine-Westphalia、德国、45147
- Universitaetsklinikum Essen
-
-
-
-
Bari
-
Bari、Bari、意大利、70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
-
Bergamo
-
Bergamo、Bergamo、意大利、24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
-
Roma
-
Roma、Roma、意大利、165
- Ospedale Pediatrico Bambino Gesù
-
Roma、Roma、意大利、168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
-
Riyadh、沙特阿拉伯、11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
Bas Rhin
-
Strasbourg、Bas Rhin、法国、67091
- CHU Strasbourg - Nouvel Hôpital Civil
-
-
Haute Garonne
-
Toulouse、Haute Garonne、法国、31059
- Hopital Rangueil
-
-
Herault
-
Montpellier、Herault、法国、34000
- Hopital Lapeyronie pt
-
-
Nord
-
Lille、Nord、法国、59037
- Hopital Claude Huriez - CHU Lille
-
-
Paris
-
Paris、Paris、法国、75015
- Hôpital Necker - Enfants Malades
-
-
Rhone
-
Lyon、Rhone、法国、69437
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
-
Lausanne、瑞士、1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
-
-
-
Helsinki、芬兰、290
- Helsinki University Central Hospital
-
-
-
-
Greater London
-
London、Greater London、英国、NW3 2QG
- Royal Free Hospital
-
London、Greater London、英国、W12 0HS
- Hammersmith Hospital
-
-
Greater Manchester
-
Manchester、Greater Manchester、英国、M13 9WL
- Manchester Royal Infirmary
-
-
Tyne & Wear
-
Newcastle upon Tyne、Tyne & Wear、英国、NE7 7DN
- Freeman Hospital
-
-
-
-
Barcelona
-
Barcelona、Barcelona、西班牙、8035
- Hospital Universitari Vall d'Hebron - VHIR
-
-
La Coruña
-
A Coruña、La Coruña、西班牙、15006
- Complejo Hospitalario Universitario A Coruña
-
-
Madrid
-
Madrid、Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
-
Málaga
-
Málaga、Málaga、西班牙、29010
- Hospital Regional Universitario de Malaga
-
-
Vizcaya
-
Barakaldo、Vizcaya、西班牙、48903
- Hospital de Cruces
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
- Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
- Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.
Exclusion Criteria:
- A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
- History of invasive meningococcal disease.
- History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Known or suspected hereditary fructose intolerance.
- Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
- Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN |
Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment:
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of Clinically Significant Recurrent Disease
大体时间:Within 2 years after kidney transplantation
|
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy |
Within 2 years after kidney transplantation
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to Onset of Clinically Significant Disease Recurrence
大体时间:Up to 2 years after kidney transplantation
|
To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation |
Up to 2 years after kidney transplantation
|
合作者和调查者
合作者
调查人员
- 研究主任:Study Physician、Swedish Orphan Biovitrum AB (publ)
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Sobi.PEGCET-404
- 2026-526392-39-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents.
All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.